Esperion's Bempedoic Acid Secures Multiple Class 1 Recommendations in Major Dyslipidemia Guidelines
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion's bempedoic acid, marketed as NEXLETOL and NEXLIZET, has received multiple Class 1 recommendations in the newly released 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia. This highest level of endorsement signifies strong evidence for the drug's efficacy in various patient populations, including those with statin intolerance and severe hypercholesterolemia, for both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). This is a highly material development for Esperion, as it significantly strengthens the market position and clinical credibility of its core product line. The guideline inclusion is expected to drive increased physician adoption and expand patient access, providing a substantial tailwind for future revenue growth following the company's recent positive financial results and strategic acquisition of Corstasis Therapeutics. Traders will be monitoring the impact on sales forecasts and market share.
At the time of this announcement, ESPR was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $626.6M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.